miRNAs - crucial pathway regulators, innovative biomarkers and promising therapeutics.
We have been focusing on innovative biomarkers at BioVendor R&D since the very beginning of the division. This meant we were amongst the first to spot the considerable potential of these short non-coding RNA sequences. These are regulators of gene expression, which are involved in most physiological processes and the pathogenesis of many diseases. Monitoring miRNA levels can be used to describe the molecular mechanism or early diagnosis of various pathologies and to identify their stages. Since 2016, miRNAs have been at the centre of our research as promising diagnostic and prognostic biomarkers.
The Two Tailed RT qPCR (TT PCR) method was developed together with leading scientists from the TATAA and BIOCEV centres. We solved the sensitivity and specificity problems caused by the short miRNA sequence by means of unique hemiprobic RT primers and specific primers for qPCR. We achieve excellent results with this combination. It is a user-friendly method based on PCR.
MicroRNA Enzymatic Immunoassay (miREIA) uses direct hybridisation of miRNA with biotinylated ssDNA to generate RNA-DNA hybrid. The hybrid is subsequently recognised by the antibody captured on the microplate. This protocol, similar to the ELISA method, does not include any amplification steps and its price in terms of sample is extremely favourable.
Knowledge panels identify expression levels of 176/352 miRNA targets. These measurements provide the basic tool for primary screening of target miRNAs. It's a great choice for any project in which you are looking for the right miRNA to quantify.
Diagnostics based on a comparison of the miRNA expression is no longer just a vision – our diagnostic panels manage to determine the current risks to the patient's health condition. Early diagnosis and correctly set treatment are key to the successful prognosis of the patient, and in both cases miRNAs are promising biomarkers.